A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants
12 Years
N/A
Both
Cancer
Trial Information
A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants
OBJECTIVES:
- Compare the occurrence of serious invasive fungal or bacterial infections during the
first 270 days after transplantation in cytomegalovirus (CMV)-negative patients
receiving a CMV-positive allogeneic stem cell transplantation and valacyclovir or
placebo.
- Compare the occurrence of primary CMV infection within the first 100 days after
transplantation in patients treated with these regimens.
- Compare the survival of these patients at 100 days and 270 days post-transplantation.
- Compare the occurrence of CMV disease at day 100 and day 270 post-transplantation in
patients treated with these regimens.
- Compare the safety of these regimens in these patients.
- Correlate the presence of CMV in stem cell product with post-transplantation CMV
infection in these patients.
- Determine if subclinical CMV infection results in a virus-specific immune response
(humoral and cellular) in these patients.
- Compare the quality of life of patients treated with these regimens.
- Compare resource utilization (e.g., rates of hospitalization, number of days alive out
of the hospital, days in the intensive care unit, days on mechanical ventilation, use
of antimicrobials and filgrastim [G-CSF], and number of invasive procedures) in
patients treated with these regimens.
OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients
are stratified according to participating center and type of transplantation (matched
related vs mismatched/unrelated). Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive oral valacyclovir 4 times daily beginning with transplantation
conditioning (usually day -5) and continuing until day 100 after transplantation.
Patients receive high-dose acyclovir, instead of valacyclovir, IV every 8 hours
beginning on day -1 and continuing until oral medications are tolerated. Allogeneic
stem cells are infused on day 0.
- Arm II: Patients receive oral or IV placebo on the same schedule as in arm I. Quality
of life is assessed at baseline and on days 50 and 100.
Patients are followed every 2 weeks for 6 months.
PROJECTED ACCRUAL: A total of 115-230 patients (58-115 per treatment arm) will be accrued
for this study within 2 years.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Disease requiring one of the following types of stem cell transplantation:
- First myeloablative allogeneic peripheral blood stem cell
- Unrelated cord blood
- Bone marrow
- Related or unrelated donor
- T-cell depleted or non-T-cell depleted
- CD34 selected or non-selected
- Patient must be cytomegalovirus (CMV)-seronegative and donor must be CMV-seropositive
- No transplantation with nonmyeloablative regimens, including any of the following:
- Fludarabine and total body irradiation (TBI) (2 Gy or less)
- TBI alone (2 Gy)
- Fludarabine, cytarabine, and idarubicin
- Fludarabine and melphalan (140 mg/m^2 or less)
- No definite or probable pre-transplantation diagnosis of invasive mold infection
(aspergillosis, fusariosis, or zygomycosis), including pulmonary or hepatic nodules
consistent with invasive mold infection for which patients are receiving targeted
prophylaxis with amphotericin or other mold-active products
- No pre-transplantation-CMV disease (gastrointestinal or pneumonia)
PATIENT CHARACTERISTICS:
Age
- 12 and over
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
Other
- HIV negative
- No hypersensitivity to acyclovir or valacyclovir
- Not pregnant
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
Chemotherapy
- See Disease Characteristics
Endocrine therapy
- Not specified
Radiotherapy
- See Disease Characteristics
Surgery
- Not specified
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care
Principal Investigator
Garrett Nichols, MD, MSC
Investigator Role:
Study Chair
Investigator Affiliation:
Fred Hutchinson Cancer Research Center
Authority:
United States: Federal Government
Study ID:
1603.00
NCT ID:
NCT00045292
Start Date:
April 2002
Completion Date:
October 2004
Related Keywords:
- Cancer
- infection
- accelerated phase chronic myelogenous leukemia
- blastic phase chronic myelogenous leukemia
- childhood chronic myelogenous leukemia
- chronic phase chronic myelogenous leukemia
- relapsing chronic myelogenous leukemia
- adult acute lymphoblastic leukemia in remission
- childhood acute lymphoblastic leukemia in remission
- recurrent adult acute lymphoblastic leukemia
- recurrent childhood acute lymphoblastic leukemia
- untreated adult acute lymphoblastic leukemia
- untreated childhood acute lymphoblastic leukemia
- adult acute myeloid leukemia in remission
- childhood acute myeloid leukemia in remission
- recurrent adult acute myeloid leukemia
- recurrent childhood acute myeloid leukemia
- secondary acute myeloid leukemia
- untreated adult acute myeloid leukemia
- untreated childhood acute myeloid leukemia and other myeloid malignancies
- atypical chronic myeloid leukemia
- chronic eosinophilic leukemia
- chronic idiopathic myelofibrosis
- chronic neutrophilic leukemia
- chronic myelomonocytic leukemia
- juvenile myelomonocytic leukemia
- de novo myelodysplastic syndromes
- myelodysplastic/myeloproliferative disease, unclassifiable
- previously treated myelodysplastic syndromes
- secondary myelodysplastic syndromes
- disseminated neuroblastoma
- recurrent neuroblastoma
- noncontiguous stage II adult diffuse large cell lymphoma
- recurrent adult diffuse large cell lymphoma
- stage III adult diffuse large cell lymphoma
- stage IV adult diffuse large cell lymphoma
- noncontiguous stage II adult Burkitt lymphoma
- recurrent adult Burkitt lymphoma
- stage III adult Burkitt lymphoma
- stage IV adult Burkitt lymphoma
- noncontiguous stage II adult diffuse mixed cell lymphoma
- recurrent adult diffuse mixed cell lymphoma
- stage III adult diffuse mixed cell lymphoma
- stage IV adult diffuse mixed cell lymphoma
- noncontiguous stage II adult diffuse small cleaved cell lymphoma
- recurrent adult diffuse small cleaved cell lymphoma
- stage III adult diffuse small cleaved cell lymphoma
- stage IV adult diffuse small cleaved cell lymphoma
- noncontiguous stage II adult immunoblastic large cell lymphoma
- recurrent adult immunoblastic large cell lymphoma
- stage III adult immunoblastic large cell lymphoma
- stage IV adult immunoblastic large cell lymphoma
- noncontiguous stage II adult lymphoblastic lymphoma
- recurrent adult lymphoblastic lymphoma
- recurrent childhood lymphoblastic lymphoma
- stage III adult lymphoblastic lymphoma
- stage IV adult lymphoblastic lymphoma
- noncontiguous stage II grade 1 follicular lymphoma
- noncontiguous stage II grade 2 follicular lymphoma
- noncontiguous stage II grade 3 follicular lymphoma
- recurrent grade 1 follicular lymphoma
- recurrent grade 2 follicular lymphoma
- recurrent grade 3 follicular lymphoma
- stage III grade 1 follicular lymphoma
- stage III grade 2 follicular lymphoma
- stage III grade 3 follicular lymphoma
- stage IV grade 1 follicular lymphoma
- stage IV grade 2 follicular lymphoma
- stage IV grade 3 follicular lymphoma
- noncontiguous stage II mantle cell lymphoma
- recurrent mantle cell lymphoma
- stage III mantle cell lymphoma
- stage IV mantle cell lymphoma
- poor prognosis metastatic gestational trophoblastic tumor
- previously treated childhood rhabdomyosarcoma
- recurrent Wilms tumor and other childhood kidney tumors
- recurrent adult Hodgkin lymphoma
- recurrent/refractory childhood Hodgkin lymphoma
- recurrent childhood rhabdomyosarcoma
- recurrent childhood large cell lymphoma
- recurrent childhood small noncleaved cell lymphoma
- recurrent cutaneous T-cell non-Hodgkin lymphoma
- recurrent mycosis fungoides/Sezary syndrome
- recurrent ovarian epithelial cancer
- recurrent ovarian germ cell tumor
- stage II ovarian epithelial cancer
- stage III ovarian epithelial cancer
- stage IV ovarian epithelial cancer
- recurrent malignant testicular germ cell tumor
- stage III malignant testicular germ cell tumor
- refractory chronic lymphocytic leukemia
- stage III chronic lymphocytic leukemia
- stage IV chronic lymphocytic leukemia
- refractory hairy cell leukemia
- refractory multiple myeloma
- stage I multiple myeloma
- stage II multiple myeloma
- stage III multiple myeloma
- stage IIIA breast cancer
- stage IIIB breast cancer
- stage IIIC breast cancer
- stage IV breast cancer
- noncontiguous stage II small lymphocytic lymphoma
- noncontiguous stage II marginal zone lymphoma
- recurrent marginal zone lymphoma
- recurrent small lymphocytic lymphoma
- stage III small lymphocytic lymphoma
- stage III marginal zone lymphoma
- stage IV small lymphocytic lymphoma
- stage IV marginal zone lymphoma
- extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
- nodal marginal zone B-cell lymphoma
- splenic marginal zone lymphoma
- childhood myelodysplastic syndromes
- Cytomegalovirus Infections
- Lymphoma, Non-Hodgkin
- Lymphoma, Large-Cell, Immunoblastic
Name | Location |
|---|---|
| Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
| Huntsman Cancer Institute | Salt Lake City, Utah 84112 |
| City of Hope Comprehensive Cancer Center | Duarte, California 91010 |
| Stanford Cancer Center at Stanford University Medical Center | Stanford, California 94305 |
| UNMC Eppley Cancer Center at the University of Nebraska Medical Center | Omaha, Nebraska 68198-7680 |
| Baylor University Medical Center | Dallas, Texas 75246 |
